Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of Directors
25 juin 2024 09h00 HE
|
Shape Therapeutics, Inc.
Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of Directors
Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain
08 mai 2024 09h31 HE
|
Shape Therapeutics, Inc.
RNAfix achieves up to 92% editing in the non-human primate brain after AAV-based gRNA delivery RNAfix achieves >95% editing throughout the mouse brain with sustained durability at least 6 months...
Shape Therapeutics Announces Appointment of Matt Valentino as Chief People Officer
02 mai 2024 08h00 HE
|
Shape Therapeutics, Inc.
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the...
Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024
30 avr. 2024 08h00 HE
|
Shape Therapeutics, Inc.
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today announced its upcoming oral presentations...
ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target
30 nov. 2023 08h00 HE
|
Shape Therapeutics, Inc.
ShapeTX announces the expansion of its drug discovery partnership with Roche with new target
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
07 sept. 2023 17h00 HE
|
Shape Therapeutics, Inc.; Otsuka
TOKYO and SEATTLE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce...
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
20 juin 2023 08h00 HE
|
Shape Therapeutics, Inc.
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief...
ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond
04 mai 2023 08h00 HE
|
Shape Therapeutics, Inc.
SEATTLE, May 04, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced seven presentations from across its technology...
ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference
05 janv. 2023 08h00 HE
|
Shape Therapeutics, Inc.
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare...
Shape Therapeutics named one of Fierce Biotech’s “Fierce 15” Companies of 2022
12 sept. 2022 09h00 HE
|
Shape Therapeutics, Inc.
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), the RNA technology company advancing programmable medicine, today announced that Fierce Biotech has named it as one of...